The Minnesota Molecular and Cellular Therapeutics Facility: A state-of-the-art biotherapeutics engineering laboratory

Transfusion Medicine Reviews

Volumn 19, Issue 3, 2005, Pages 217-228

  McKenna, David H ^a   Kadidlo, Diane M ^b   Miller, Jeffrey S ^b   Orchard, Paul J ^b   Wagner, John E ^b   McCullough, Jeffrey ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE;

ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC STEM CELL TRANSPLANTATION; BONE MARROW TRANSPLANTATION; GENETIC ENGINEERING; GRAFT VERSUS HOST REACTION; HEALTH CARE POLICY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LABORATORY TEST; MOLECULAR DYNAMICS; MYOBLAST; NONHUMAN; REVIEW; T LYMPHOCYTE; UMBILICAL CORD BLOOD;

ACADEMIC MEDICAL CENTERS; BIOLOGICAL PRODUCTS; BONE MARROW TRANSPLANTATION; CANCER VACCINES; CLINICAL TRIALS; ENGINEERING; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELLS; HUMANS; KILLER CELLS, NATURAL; LABORATORIES; LYMPHOCYTE ACTIVATION; MINNESOTA;

EID: 21744452130     PISSN: 08877963     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tmrv.2005.02.007     Document Type: Review

References (36)

1. J.S. Ross, D.P. Schenkein, and R. Pietrusko Targeted therapies for cancer 2004 Am. J. Clin. Pathol. 122 2004 598 609
2. S.N. Malek, and I.W. Flinn Incorporating monoclonal antibodies in blood and marrow transplantation Semin. Oncol. 30 2003 520 530
3. C. Bordignon, C. Carlo-Stella, and M.P. Colombo Cell therapy: Achievements and perspectives Haematologica 84 1999 1110 1149
4. S.M. Selkirk Gene therapy in clinical medicine Postgrad. Med. J. 80 2004 560 570
5. US Food and Drug Administration Current good manufacturing practices for finished pharmaceuticals. Code of Federal Regulations. Title 21 CFR Part 211 2004 U.S. Government Printing Office Washington, DC (revised annually)
6. US Food and Drug Administration Current good tissue practice for manufacturers of human cellular and tissue-based products; inspection and enforcement; final rule Docket No. 19977N-484P Fed. Regist. 69 2004 68612 68688
7. US Food and Drug Administration Establishment registration and listing for manufacturers of human cellular and tissue-based products; final rule Fed. Regist. 66 2001 5447 5469
8. US Food and Drug Administration Points to consider in the manufacture and testing of monoclonal antibody products for human use 1997 Center for Biologics Evaluation and Research
9. US Food and Drug Administration Guidance for industry: Guidance for human somatic cell therapy and gene therapy 1998 Center for Biologics Evaluation and Research
10. Foundation for the Accreditation of Cellular Therapy (FACT) Standards for hematopoietic progenitor cell and cellular services ed 2 2002 Foundation for the Accreditation of Cellular Therapy North America
11. American Association of Blood Banks (AABB) Standards for hematopoietic progenitor cell and cellular product services ed 3 2002 American Association of Blood Banks Bethesda, MD
12. A.P. Gee Manufacturing cellular therapy products in an academic facility Bioprocessing 1 2003 39 43
13. S.R. Burger Design and operation of a current good manufacturing practices cell-engineering laboratory Cytotherapy 2 2000 111 122
14. J. McCullough, J. Wagner, and A. Gee Production assistance for cellular therapies Transfusion 44 2004 1793 1794 (letter-to-the-editor)
15. P. Rubinstein, L. Dobrila, and R.E. Rosenfield Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution Proc. Natl. Acad. Sci. U. S. A. 92 1995 10119 10122
16. K. Mascotti, J. McCullough, and S.R. Burger HPC viability measurement: Trypan blue versus acridine orange and propidium iodide Transfusion 40 2000 693 696
17. S.R. Burger, D. Kadidlo, and J. McCullough Improved progenitor assay standardization using peripheral blood progenitor cells from a donor treated with granulocyte-colony-stimulating factor Transfusion 39 1999 451 456
18. J. McCullough Quality assurance and good manufacturing practices for processing hematopoietic progenitor cells J. Hematother. 4 1995 493 501
19. S.T. Bennett, N.L. Johnson, and L.C. Lasky Quality assurance and standards in hematopoietic progenitor processing J. Clin. Apheresis 7 1992 138 144
20. D.H. McKenna, D.M. Kadidlo, and D. Sumstad Development and operation of a quality assurance system for deviations from standard operating procedures in a clinical cell therapy laboratory Cytotherapy 5 2003 314 322
21. J. McCullough, D. McKenna, and D. Kadidlo Issues in the quality of umbilical cord blood (UCB) stem cells for transplantation Transfusion 2005 (in press)
22. D. McKenna The cell therapy program at the University of Minnesota: A collaborative approach facilitating the delivery of therapies from bench to bedside Transfus. Med. Hemother. 31 2004 2 (abstr, suppl 3)
23. J.S. Miller, Y. Soignier, and A. Panoskaltsis-Mortari Successful remission of poor prognosis AML after adoptive transfer and in vivo expansion of human haploidentical NK cells Blood 104 2004 77a (abstr, suppl)
24. M.S. Mitchell, J. Kan-Mitchell, and P.R. Morrow Phase I trial of large multivalent immunogen derived from melanoma lysates in patients with disseminated melanoma Clin. Cancer Res. 10 2004 76 83
25. P.J. Orchard, B.R. Blazar, and S. Burger Clinical-scale production of anti-CD3/CD28-activated T cells after transduction with a retroviral vector expressing herpes simplex virus thymidine kinase and truncated nerve growth factor receptor Hum. Gene Ther. 13 2002 979 988
26. Y. Jiang, B.N. Jahagirdar, and R.L. Reinhardt Pluripotency of mesenchymal stem cells derived from adult marrow Nature 418 2002 41 49
27. P.A. Taylor, C.J. Lees, and B.R. Blazar The infusion of ex vivo activated and expanded CD4+ CD25+ immune regulatory cells inhibits graft-versus-host disease lethality Blood 99 2002 3493 3499
28. W.R. Godfrey, Y.G. Ge, and D.J. Spoden In vitro-expanded human CD4+CD25+ T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures Blood 104 2004 453 461
29. E.J. van den Bos, B.H. Davis, and D.A. Taylor Transplantation of skeletal myoblasts for cardiac repair J. Heart Lung Transplant. 23 2004 1217 1227
30. L.J. Burns, D.J. Weisdorf, and T.E. DeFor IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: A phase I/II trial Bone Marrow Transplant. 32 2003 177 186
31. M.F. Mescher Surface contact requirements for activation of cytotoxic T lymphocytes J. Immunol. 149 1992 2402 2405
32. M.F. Mescher, and J.D. Rogers Immunotherapy of established murine tumors with large multivalent immunogen and cyclophosphamide J. Immunother. 19 1996 102 112
33. M.F. Mescher, and E. Savelieva Stimulation of tumor specific immunity using tumor cell plasma membrane antigen Methods 12 1997 155 164
34. D. McKenna, N. Bostrom, and D. Kadidlo Production of large multivalent immunogen vaccine in a cGMP/cGTP cellular therapy facility Transfusion 42 2002 79S (abstr, suppl)
35. J. Barker, D.J Weisdorf, and T.E. DeFor Transplantation of two partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy Blood ed 1 2004 (paper, pre-published online October 5)
36. J.D. McMannis, and R.E. Champlin Role of the GMP facility for adoptive immunotherapy Cytotherapy 4 2002 329 331